A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers

• Published in: Journal of clinical pharmacology Vol. 40; no. 12 Pt 2; p. 1509
• Main Authors: Greenberg, H E, Gottesdiener, K, Huntington, M, Wong, P, Larson, P, Wildonger, L, Gillen, L, Dorval, E, Waldman, S A
• Format: Journal Article
• Language: English
• Published: England 01.12.2000
• Subjects: Adolescent; Adult; Aspirin - administration & dosage; Aspirin - pharmacology; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors - adverse effects; Cyclooxygenase Inhibitors - pharmacology; Double-Blind Method; Drug Interactions; Female; Humans; Isoenzymes - drug effects; Isoenzymes - metabolism; Lactones - adverse effects; Lactones - pharmacology; Male; Membrane Proteins; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - pharmacology; Prostaglandin-Endoperoxide Synthases - drug effects; Prostaglandin-Endoperoxide Synthases - metabolism; Sulfones; Thromboxane B2 - blood

The present study examined whether rofecoxib (VIOXX), a new specific inhibitor of cyclooxygenase-2 (COX-2), would interfere with the desired antiplatelet effects of aspirin. Thus, the effects of rofecoxib on inhibition of ex vivo serum-generated thromboxane B2 (TXB2) and platelet aggregation by low...